Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × Recurrence × binimetinib × Clear all

Phase

Phase 2 1 Phase 1/2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Melanoma 4 Neoplasm Metastasis 3 Lung Neoplasms 2 Gastrointestinal Stromal Tumors 2 Carcinoma, Non-Small-Cell Lung 2 Uveal Melanoma 1 Triple Negative Breast Neoplasms 1 Solid Tumors Harboring a BRAF V600 Mutation 1 Solid Tumor 1 Soft Tissue Neoplasms 1 Recurrence 1 Colorectal Neoplasms 1 Breast Neoplasms 1 Brain Neoplasms 1 Biliary Tract Neoplasms 1

Interventions

Dexamethasone 24 Cyclophosphamide 21 venetoclax 17 fludarabine 12 Lenalidomide 12 Bortezomib 12 pembrolizumab 11 Cytarabine 11 Carboplatin 10 Calcium Dobesilate 10 Rituximab 8 pomalidomide 7 Nivolumab 7 Gemcitabine 7 Azacitidine 7 fludarabine phosphate 6 carfilzomib 6 selinexor 5 daratumumab 5 blinatumomab 5 Temozolomide 5 Decitabine 5 Cisplatin 5 Bendamustine Hydrochloride 5 obinutuzumab 4 ibrutinib 4 elotuzumab 4 Methotrexate 4 Etoposide 4 Cetuximab 4

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04292119 2021-03-10

Lorlatinib Combinations in Lung Cancer

Massachusetts General Hospital

Phase 1/2 Unknown

Lung Neoplasms, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon ⚡